Work

Dabrafenib in Patients with Braf V600E-Mutant Advanced Non-Small Cell Lung Cancer (Nsclc): a Multicenter, Open-Label, Phase Ii Trial (Brf113928)

Year: 2014

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdu438.46

Authors: D. Planchard, T.M. Kim, J. Mazieres, E. Quoix, G.J. Riely, F. Barlesi, P. Souquet, E.F. Smit, H.J.M. Groen, R.J. Kelly, B. Cho, M.A. Socinski, C. Tucker, B. Ma, B. Mookerjee, C.M. Curtis, B.E. Johnson

Institutions: Institut Gustave Roussy, Seoul National University Hospital, Hôpital Rangueil, Hôpital Larrey, Hôpitaux Universitaires de Strasbourg, Memorial Sloan Kettering Cancer Center, Aix-Marseille Université, Hôpital Lyon Sud, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, University Medical Center Groningen, University of Groningen, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Yonsei University, University of Pittsburgh, GlaxoSmithKline (United States), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W1957531516

FWCI: 6.958

Cites:

Cited by: 28

Related to: 10